非糖尿病IgA肾病患者使用非奈利酮的疗效与安全性
该回顾性研究纳入382例原发性IgA肾病患者,比较非奈利酮组与对照组的肾脏完全缓解率及肾脏终点事件。非奈利酮显著提高完全缓解率(HR 2.58)并降低肾脏终点事件(HR 0.30),且与SGLT2i联用缓解率更高,血钾水平两组一致。
要点
- 非奈利酮显著提高非糖尿病IgA肾病患者肾脏完全缓解率。
- 非奈利酮降低eGFR下降30%的肾脏终点事件风险。
- 非奈利酮联合SGLT2i较单用有更高的肾脏缓解率。
核心结论
- 非奈利酮治疗非糖尿病IgA肾病患者安全有效,联合SGLT2i完全缓解率更高。
研究设计与样本
- 回顾性分析2023年9月至2025年6月接受标准治疗的原发性IgA肾病患者382例,非奈利酮组与对照组各191例。
主要发现
- 非奈利酮组完全缓解率显著高于对照组(HR 2.58,95%CI 1.82-3.66,P < .001)。
- 非奈利酮组肾脏终点事件风险显著低于对照组(HR 0.30,95%CI 0.07-0.91,P = .036)。
- 非奈利酮联合SGLT2i的肾脏缓解率高于未联用者(联用HR 3.52,95%CI 2.32-5.35;未联用HR 1.54,95%CI 0.75-3.19,Pinteraction = .032)。
- 两组血清钾水平保持一致。
关键数值与推荐
- 完全缓解定义为24小时尿蛋白定量<0.5 g/day。
- 肾脏终点事件定义为估算肾小球滤过率(eGFR)下降30%。
临床怎么用
- 非糖尿病IgA肾病患者可考虑使用非奈利酮以促进肾脏缓解,联用SGLT2i可能进一步获益。
局限性
- 回顾性研究设计可能存在选择偏倚,单中心及样本量有限,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Finerenone has been proven to have cardiovascular and renal protective effects on chronic kidney disease associated with type 2 diabetes. However, the therapeutic effect of finerenone on IgA nephropathy (IgAN) without diabetes remains unclear. METHODS: A retrospective analysis was conducted on patients with primary IgAN who received standard treatment between September 2023 and June 2025. The patients were divided into the finerenone and control groups based on whether finerenone was used. The primary outcomes were the renal complete response (CR) rate (<0.5 g/day) and renal endpoint events [defined as a 30% reduction in estimated glomerular filtration rate (eGFR)], and the secondary outcomes were the degree of decrease in 24-h urine protein quantification, changes in eGFR and safety outcomes. RESULTS: A total of 382 patients were included (191 in the finerenone group and 191 in the control group). Finerenone significantly increased the CR rate compared with the control group [hazard ratio (HR) 2.58, 95% confidence interval (CI) 1.82-3.66, P < .001] and reduced the renal endpoint event (HR 0.30, 95% CI 0.07-0.91, P = .036). Finerenone combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) had a higher renal remission rate (with SGLT2i: HR 3.52, 95% CI 2.32-5.35; without SGLT2i: HR 1.54, 95% CI 0.75-3.19, Pinteraction = .032). The serum potassium levels in both groups remained consistent. CONCLUSION: Finerenone is safe and effective in treating IgAN patients without diabetes, and finerenone combined with SGLT2i has a higher CR rate.
引用
- Wang J, Tu Y, Chen Z, et al. Efficacy and safety of finerenone in non-diabetic patients with IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 41649423. doi:10.1093/ndt/gfag023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。